FDA Investigator Jo Annc Declement
Jo Annc Declement has conducted inspections on 135 sites in 3 countries as of 20 Oct 2021. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
135
Last Inspection Date:
20 Oct 2021
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
Poland,
Canada
FDA Investigators that have inspected at least one site in common with Jo Annc Declement:
Amos C Epps,
Amy L Singer,
Annemarie Bodnar,
Anthony M Criscuolo, Jr,
Antoinette L Ravelli,
Austin B Appler,
Barbara J Maulfair,
Brandi L Garbutt,
Brandon L Mariner,
Brant M Schroeder,
Brian D Young,
Carol A Perry,
Carol A Robles,
Cary Greene,
Clara E Santiago,
Craig W Swanson,
Cynthia White,
Deborah J Parris,
Derek S Dealy,
Devon Jenkins,
Dhaval H Patel,
Donyel M Jones,
Doreen P Gubbay,
Edward O'shaughnessy,
Emest F Bizjak,
Gerald W Kopp,
Gianine E Delade,
Gillian B Nardelli,
Hitesh R Patel,
Janaye A Young,
Jennifer A Bazergui,
Jennifer Macmillan,
Jesse N Nardone,
Jesse Ray N Nardone,
Jessica M Monteiro,
Jill M Sooter,
Jill Mielziner,
Joseph T Dougherty,
Judith A Jones,
Judith A Paterson,
Justine Tomasso,
Karen F Tomaziefski,
Keith A Schwartz,
Kelli F Dobilas,
Kerry A Kurdilla,
Kris K Moore,
Kristen E Rescigno,
Krystyna M Kitson,
Kyle D Covill,
Loretta Nemchik,
Marcelo O Mangalindan, Jr,
Marea K Harmon,
Margaret M Sands,
Melka F Argaw,
Meredith L Sheridan,
Michael R Klapal,
Michael Rosner,
Nerizza B Guerin,
Nina Yang,
Ramanda C Gregory,
Ray Niles,
Raymond Cheung,
Raymond L Cheung,
Raymond Niles,
Regina T Brown,
Remache,
Richard D Manney,
Robert W Calais,
Robert W Mccullough,
Ronald T Colucci,
Russell J Glapion,
Russell P Vandermark,
Ruth A Oni,
Sarah J Park,
Schultz,
Seng Ching Hwang,
Sharon Ferraro,
Sierra M Shockley,
Stephanie T Durso,
Tamil Arasu, PhD,
Teigan M Mule,
Tressa T Lewis,
Tyanna N Hadley,
Valerie C Reed,
Wayne J Meyer,
William J Muszynski,
William W Dotts,
Willy A Orantes
Jo Annc Declement's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2015 | EIR | Southport Distribution, LLC - EIR, 2015-10-16 |
November, 2010 | FDA 483 | Gaspari Nutra LLC - Form 483, 2010-11-01 |
November, 2010 | EIR | Gaspari Nutra LLC - EIR, 2010-11-01 |
January, 2009 | EIR | Steven J. Glass, M.D. - EIR, 2009-01-26 |
October, 2021 | EIR | MOL LOGISTICS (USA) INC. - EIR, 2021-10-20 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more